In response to a reader's query about possible conflicts of interest relative to a Letter to the Editor published in the May issue of the Journal (O'Brien JM. 17-hydroxy progesterone caproate, progesterone, preterm birth prevention, and safety; who decides? Someone should. Am J Obstet Gynecol 2011;204:5.e16-7) Dr John O'Brien wishes to disclose the following:
- (1)He was involved in studies of progesterone gel treatment for preterm birth prevention, financially supported by Columbia Laboratories, a maker of progesterone gel.
- (2)He serves on Advisory Boards for Watson Pharmaceuticals, a company with a financial interest in marketing vaginal progesterone gel for preterm birth prophylaxis.
- (3)He acknowledges that he and others are listed in the patent on the use of all progesterone compounds to prevent preterm birth (US Patent Number 7,884,093: Progesterone for the Treatment and Prevention of Spontaneous Preterm Birth).
Article info
Identification
Copyright
© 2011 Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- 17-hydroxyprogesterone caproate, progesterone, preterm birth prevention, and safety: who decides? Someone shouldAmerican Journal of Obstetrics & GynecologyVol. 204Issue 5
- PreviewThe synthetic progestin 17-hydroxyprogesterone caproate (17-OHP-C) and natural progesterone differ remarkably in their structure and relative affinity for progesterone receptors (the binding affinity of 17OHP-C is only 26-30% of the binding affinity of progesterone).1 Furthermore, the synthetic is not metabolized into a naturally occurring compound.2 This varied biochemistry may elicit varied responses, which have been observed in laboratory experiments (some of which are negative regarding exposure to the synthetic).
- Full-Text
- Preview
